How cannabis commercialization may shape psychiatric risk

This Viewpoint asks how policies that shape cannabis commercialization may function as a modifiable public health exposure. Rather than testing a specific cannabis product or treatment in a defined population, it considers whether the way cannabis is produced, marketed, and sold could influence psychiatric risk.

The authors propose that commercialization policies may offer opportunities for prevention and describe potential mitigation strategies. The abstract reports no quantitative results and does not specify a study population, sample, comparator, or follow-up period. As an abstract-based summary, this paper cannot establish that commercialization causes psychiatric harm, identify which policies are most influential, or determine whether any proposed mitigation strategy is effective.